REFERENCES

1. Wilson JMG, Jungner G. Principles and Practice of Screening for Disease. Public Health Papers No. 34. Geneva: World Health Organization; 1968.

2. Andermann A, Blancquaert I, Beauchamp S, Dery V Revisiting Wilson and Jungner in the genomic age: a review ofscreening criteria over the past 40 years.

3.Cuckle H. Principles of screening. Obstet Gynaecol 2004;6:21-25.

4. Bretthauer M, Kalager M. Principles, effectiveness and caveats in screening for cancer. Br J Surg 2013;100:55-65.

5. Trivedi AN, Rakowski W, Ayanian JZ. Effect of cost sharing on mammography in Medicare Health plans. N Engl J Med 2008;358:3375-83.

6. Jorgensen KJ, Brodersen J, Hartling OJ, Nielsen M, Gotzsche PC. Informed choice requires information about benefits and harms. J Med Ethics 2009;35:268-69.

7. Arbyn M, Castellesague X, de Sanjose S, et al. World-wide burden of cervical cancer in 2008. Ann Oncol 2011;22:2675-83.

8. Swaminathan, R, Selvakumaran R, Vinodha J, et al. Education and cancer incidence in a rural population in South India. Cancer Epidemiol 2009;33:89-93.

9. Prummel MV, Young DW, Candido E, et al. Cervical cancer inci­dence in Ontario women: differing sociodemographic gradients by morphologic type (adenocarcinoma versus squamous cell). Int J Gynecol Cancer 2014;24:1341-46.

10. Papanicolaou GN. New cancer diagnosis. In: Proceedings of the Third Race Betterment Conference, pp. 528-34. Battle Creek, MI: Race Betterment Foundation; 1928.

11. Papanicolaou GN, Traut HF. The diagnostic value of va­ginal smears in carcinoma of the uterus. Am J Obstet Gynecol 1941;August:193-206.

12. Papanicolaou GN. Atlas of Exfoliative Cytology. Boston, MA: Commonwealth Fund University Press; 1954.

13. IARC Working Group on Cervical Cancer Screening. Summary chapter. In: Hakama M, Miller AB, Day NE (eds), Screening for Cancer of the Uterine Cervix, pp.

14. Laara E, Day NE, Hakama M. Trends in mortality from cer­vical cancer in the Nordic countries: association with organised screening programmes. Lancet 1987;1:1247-49.

15. IARC Working Group on Evaluation of Cervical Cancer Screening Programmes. Screening for squamous cervical cancer: the dur­ation of low risk after negative result of cervical cytology and its implication for screening policies. Br Med J 1986;293:659-64.

16. Hakama M, Louhivuori K. A screening programme for cervical cancer that worked. Cancer Surv 1988;17:403-16.

17. van Oortmarssen GJ, Habbema JD. Cervical cancer screening data from two cohorts in British Columbia. In: Hakama M, Miller AB, Day NE (eds), Screeningfor Cancer of the Uterine Cervix, pp. 47-60. IARC Scientific Publications No. 76. Lyon: International Agency for Research on Cancer; 1986.

18. Sasieni PD, Cuzick J, Lynch-F armery E, The National Co­ordinating Network for Cervical Screening Working Group. Estimating the efficacy of screening by auditing smear his­tories of women with and without cervical cancer. Br J Cancer 1996;73:1001-1005.

19. Royal College of Obstetricians and Gynaecologists (RCOG). Progress in Cervical Screening in the UK. Scientific Impact Paper No.7. London: RCOG; 2016.

20. Herbert A, Anshu CG, Dunsmore H, et al. Invasive cervical cancer audit: why cancers developed in a high risk population with an organised screening programme. BJOG 2010;117:736-45.

21. Parkin DM. Screening for cervix cancer in developing coun­tries. In: Miller AB, Chamberlain J, Day NE, Hakama M, Prorok PC (eds), Cancer Screening, pp 184-98. Cambridge: Cambridge University Press; 1991.

22. Sankaranarayanan R, Swaminathan R, Brenner H, et al. Cancer survival in Africa, Asia and Central America: a population based study. Lancet Oncol 2010;11:165-73.

23. Gondos A, Brenner H, Wabinga H, Parkin DM. Cancer survival in Kampala, Uganda. Br J Cancer 2005;92:1808-12.

24. Gakidou E, Nordhagen S, Obermeyer Z. Coverage of cervical cancer screening in 57 countries: low average levels and large in­equalities. PloS Med 2008;5:e132.

25. Luthra UK, Rengachari R. Organisation of screening programmes in developing countries with reference to screening for cancer of the uterine cervix in India. In: Hakama M, Miller AB, Day NE (eds), Screeningfor Cancer of the Uterine Cervix, pp.273-85. IARC Scientific Publications No. 76. Lyon: International Agency for Research on Cancer; 1986.

26. Shastri SS, Mittra I, Gauravi AM, et al. Effect of VIA screening by primary health workers: randomized controlled study in Mumbai, India. J Natl CancerInst 2014;106:dju009.

27. Parham GP, Mwanahamuntu MH, Kapambwe S, et al. Population­level scale-up of cervical cancer prevention services in a low-re­source setting: development, implementation, and evaluation of the Cervical Cancer Prevention Program in Zambia. PLoS One 2015;10:e0122169.

28. World Health Organization (WHO). Prevention of Cervical Cancer through Screening Using Visual Inspection with Acetic Acid (VIA) and Treatment with Cryotherapy: A Demonstration Project in Six African countries: Malawi, Madagascar, Nigeria, Uganda, the United Republic of Tanzania, and Zambia. Geneva: WHO; 2012.

29. Allemani C, Weir HK, Carreira H, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 2015;385:977-1010.

30. De Sanjose S, Quint WG, Alemany L, et al. Human papilloma­virus genotype attribution in invasive cervical cancer: a retro­spective cross-sectional worldwide study. Lancet Oncol 2010; 11: 1048-56.

31. Denny L, Adewole I, Anorlu R, et al. Human papillomavirus prevalence and type distribution in invasive cervical cancer in Sub-Saharan Africa. Int J Cancer 2013;134:1389-98.

32. Denny L, Kuhn L, Hu CC, Tsai WY, Wright TC Jr. Human pap­illomavirus-based cervical cancer prevention: long-term results of a randomized screening trial.

33. Sankaranayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009;360:1385-94.

34. Ronco G, Dillner J, Elfstrom KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow up of four European randomised controlled trials. Lancet 2014;383:524-32.

35. Jeronimo J, Bansil P, Lim J, et al. A multicountry evaluation of careHPV testing, visual inspection with acetic acid, and Papanicolaou testing for the early detection of cervical cancer. Int J Gynecol Cancer 2014;24:576-84.

36. Kuhn L, Saidu R, Svanholm-Barrie C, et al. HPV testing of self­collected vaginal swabs for cervical cancer prevention in South Africa. Abstract # 60. 4th Annual Symposium on Global Cancer Research. San Francisco, CA, 8 April 2016.

37. Kuhn L, Saidu R, Boa R, et al. Optimizing point-of-care HPV testing for cervical cancer prevention in South Africa. EUROGIN 2016; Saltzburg Austria, 15-18 June 2016.

38. Ladner J, Besson MH, Rodrigues M, Audureau E, Saba J. Performance of 21 HPV vaccination programs implemented in low and middle-income countries, 2009-2013. BMC Public Health 2014;14:670.

39. Hansen C, Eckert L, Bloem P, Cernuschi T. Gavi HPV programs: ap­plication to implementation. Vaccine (Basel) 2015;3:408-19.

40. International Agency for Research on Cancer. Global Cancer Observatory. Available at: http://globocan.iarc.fr/old/factsheet. asp (accessed 21 June 2016).

41. Rubin SC, Benjamin I, Behbakht K, et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA 1. N Engl J Med 1996;335:1413-16.

42. U.S. Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med 2005;143:355-61.

43. Risch HA, McLaughlin JR, Cole DE, et al. Population BRCA 1 and BRCA 2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.

44. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.

45. Cass I, Baldwin RL, Varkey T, et al. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003;97:2187-95.

46. Tan DSP, Rothermundt C, 'Thomas K, et al. ‘BRCA-ness syndrome in ovarian cancer: a case-control study describing the clinical fea­tures and outcome of patients with epithelial ovarian cancer associ­ated with BRCA 1 and 2 mutations. J Clin Oncol 2008;26:5530-36.

47. Alsop K, Fereday S, Meldrum C, et al. BRCA mutation frequency and patterns of treatment Response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 2012;30:2654-63.

48. McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensi­tivity to poly (ADP-ribose) polymerase inhibition. Cancer Res 2006;66:8109-115.

49. Prat J. Pathology of the Ovary. Philadelphia, PA: Saunders; 2004.

50. Gilks CB, Prat J. Ovarian carcinoma pathology and genetics: re­cent advances. Hum Pathol 2009;40:1213-23.

51. Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations and clinicopathological features. Virchows Arch 2012;460:237-49.

52. Fields MM, Chevlen E. Ovarian cancer screening: a look at the evidence. Clin J Oncol Nurs 2006;10:77-81.

53. Jacobs IJ, Menon U, Ryan A, et al. Ovarian Cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 2016;387:945-56.

54. Narod S, Sopik V Should we screen for ovarian cancer? A com­mentary on the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Gynecol Oncol 2016;141:191-94.

55. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oo­phorectomy in carriers of BRCA1 or BRCA 2 mutations. N Engl J Med 2002;346:1616-22.

56. Crum CP, Dropkin R, Kindelberger D, Medeiros F, Miron A, Lee Y. Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res 2006;5:35-44.

57. Kurman RJ, Shih IM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—shifting the paradigm. Hum Path 2011;142:918-31.

58. Bowrell DDL. The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer 2010;31:161-69.

59. Cibula D, Zikan M, Dusek L, Majek O. Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis. Expert Rev Anticancer Ther 2011;11:1197-207.

60. Cibula D, Widschwendter M, Zikan M, Dusek L. Underlying mechanisms of ovarian cancer risk reduction after tubal ligation. Acta Obstet Gynecol Scand 2011;90;559-63.

61. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA 1 and BRCA 2 mutation. N Engl J Med 2002;346:1609-15.

62. McAlpine J, Hanley G, Woo M, et al. Opportunistic salpingec­tomy: uptake, risks and complications of a regional initiative for ovarian cancer prevention. Am J Obstet Gynecol 2014; 210:471-73.

63. International Agency for Research on Cancer, World Health Organization. GLOBOCAN: estimated incidence, mortality and prevalence of cancer worldwide in 2012. Available at: http:// globocan.iarc.fr/Pages/Fact_sheets_population.aspx (accessed 17 May 2015).

64. Watson P, Vasen HF, Mecklin JP, et al. The risk of endometrial cancer in hereditary nonpolyposis colorectal cancer. Am J Med 1994;96:516-20.

65. Aanio M, Mecklin JP, Aaltonen LA, et al. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer 1995;64:430-33.

66. Weiderpass E, Adami HO, Baron JA, et al. Use of oral contra­ceptives and endometrial cancer risk (Sweden). Cancer Causes Control 1999;10:277-84.

67. Moradi T, Nyren O, Bergstrom R, et al. Risk for endometrial cancer in relation to occupational physical activity: a nationwide cohort study in Sweden. Int J Cancer 1998;76:665-70.

68. Lukanova A, Lundin E, Micheli A, et al. Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int J Cancer 2004:108:425-32.

69. Esposito K, Chiodini P, Capuano A, et al. Metabolic syndrome and endometrial cancer: a meta-analysis. Endocrine 2014;45: 28-36.

70. Smith DC, Prentice R, Thompson DJ, et al. Association of ex­ogenous estrogen and endometrial cancer. N Engl J Med 1975;292:1167-70.

71. Antunes CM, Strolley PD, Rosenshein NB, et al. Endometrial cancer and estrogen use. Report of a large case-control study. N Engl J Med 1979;300:9-13.

72. Austin DF, Roe KM. The decreasing incidence of endomet­rial cancer: public health implications. Am J Public Health 1982;72:65-68.

73. Ali AT. Reproductive factors and the risk of endometrial cancer. Int J Gynecol Cancer 2014:24:384-93.

74. Beral V, Bull D, Reeves G, et al. Endometrial cancer and hor­mone replacement therapy in the Million Women Study. Lancet 2005;365:1543-51.

75. National Heart, Lung, and Blood Institute. Women’s Health Initiative (WHI). https://www.nhlbi.nih.gov/whi/whi_faq.htm (accessed 17 May 2016).

76. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hor­mone therapy and health outcomes during the intervention and extended post-stopping phases of the Women’s Health Initiative Randomized Trials. JAMA 2013:310:1353-68.

77. Wolfman W, Leyland N, Heywood M, et al., Asymptomatic endo­metrial thickening. J Obster Gynecol Cancer 2010;32:990-99.

78. Van Haneqem N, Prins MM, Bongers MY, et al., The accuracy of endometrial sampling in women with postmenopausal bleeding: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol 2016;197:147-55.

79. Van Beurden M, ten Kate FW, Tjong-A-Hung SP, et al. Human papillomavirus DNA in multicentric vulvar intraepithelial neo­plasia. Int J Gynecol Pathol 1998;17:12-16.

80. Rolfe KJ, MacLean AB, Crow JC, Benjamin E, Reid WM, Perrett CW TP53 mutations in vulval lichen sclerosus adjacent to squa­mous cell carcinoma of the vulva. Br J Cancer 2003;89:2249-53.

81. Akhtar-Danesh N, Elit L, Lytwyn A. Trends in incidence and survival of women with invasive vulval cancer in the United States and Canada: a population-based study. Gynecol Oncol 2014;134:314-18.

82. Baandrup L, Varbo A, Munk C, Johansen C, Frisch M, Kjaer SK. In situ and invasive squamous cell carcinoma of the vulva in Denmark 1978-2007—a nationwide population-based study. Gynecol Oncol 2011;122:45-49.

83. De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009;124: 1626-36.

84. International Agency for Research on Cancer (IARC). Human Papillomavirus. IARC Monographs on the Evaluation of Carcinogenic Risks in Humans, Vol. 90. Lyon: IARC Press; 2007.